Who is sponsoring NCT04294784?

NCT04294784 is sponsored by Huazhong University of Science and Technology.

What condition does NCT04294784 study?

NCT04294784 studies Gastric Cancer, GastroEsophageal Cancer.

Is NCT04294784 still recruiting?

NCT04294784 is currently terminated. Last updated 4 November 2024.

Last reviewed 2024-11-04 · How we verify

NCT04294784

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer

Terminated Phase 2 Last updated 4 November 2024

What this trial tests

Phase 2 trial testing Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor) in Gastric Cancer in 58 participants. Terminated before completion.

Timeline

3 April 2020

Primary endpoint
30 November 2023

30 November 2023

Quick facts

Lead sponsor	Huazhong University of Science and Technology
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	58
Start date	3 April 2020
Primary completion	30 November 2023
Estimated completion	30 November 2023
Sites	1 location across China

Drugs / interventions tested

Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor) — full drug profile →
Albumin-bound Paclitaxel — full drug profile →

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →
GastroEsophageal Cancer — all drugs for GastroEsophageal Cancer →

Sponsor

Huazhong University of Science and Technology

Who can join

Adults 18 to 70, any sex, with Gastric Cancer or GastroEsophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Multi-center, Open-label, Randomized Controlled,phase 2 clinical trail of Albumin-bound Paclitaxel Plus SHR-1210 （PD-1 inhibitor）Versus Albumin-bound Paclitaxel as Second-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Immune checkpoint inhibitors in gastrointestinal malignancies: an Umbrella review.
Noori M, Jafari-Raddani F, Davoodi-Moghaddam Z, Delshad M, et al · · 2024 · cited 17× · PMID 38183112 · DOI 10.1186/s12935-023-03183-3
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, et al · · 2020 · cited 14× · PMID 33210731 · DOI 10.1002/14651858.cd012078.pub2
Multi-center phase II study of nab-paclitaxel plus camrelizumab versus nab-paclitaxel alone as second-line treatment for advanced gastric cancer.
Sun L, Gong Z, Wang L, Kuang L, et al · · 2025 · PMID 40554667 · DOI 10.1093/oncolo/oyaf189
Prognostic and predictive factors in advanced upper gastrointestinal cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis of the current evidence.
Wang P, Chen P, Yang W, Yang W, et al · · 2024 · PMID 39385078 · DOI 10.1186/s12885-024-12998-w
Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer–Narrative Review
Poniewierska-Baran A, Sobolak K, Niedźwiedzka-Rystwej P, Plewa P, et al · · 2024

Verify or expand the search:

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07502027 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Tr · Phase 4 · not yet recruiting
NCT07502014 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruqui · Phase 2 · not yet recruiting
NCT07509866 — Liposomal Bupivacaine Versus Ropivacaine With Perineural Dexamethasone or Dexmedetomidine as Adjuncts for Adductor Canal · NA · recruiting
NCT07326943 — Minimum Effective Dose of Ropivacaine for Ultrasound-guided Interscalene Block · NA · recruiting
NCT07229976 — Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04294784 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huazhong University of Science and Technology
Last refreshed: 4 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04294784.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing